Rubius Therapeutics, Inc. (NASDAQ:RUBY) was founded in 2013 and is headquartered in Cambridge, Massachusetts, with 83 full-time employees (6/15/2018). It is a biotechnology company that is developing a new class of drugs, red blood cell therapy drugs (Red Cell Therapeutics, RCT).
Rubius Therapeutics (RUBY):
Based on the insights of Rubius Therapeutics, Inc., human red blood cells are the basis of the next major medical innovation. The company has designed a proprietary platform for genetic engineering and cultivation of RCTs, which are selective and effective And ready-to-use cell therapy. The company believes that its randomized controlled trials will provide life-changing or life-saving possibilities for patients with severe diseases in multiple therapeutic areas.
Rubius Therapeutics, Inc. uses its highly versatile and proprietary cell therapy platform-Rubius Erythrocyte Design Platform (RED) to generate hundreds of RCTs. The company is using its general engineering and manufacturing processes to promote a wide range of RCT product drug candidates to clinical trials for rare diseases, cancers and autoimmune diseases.
Rubius Therapeutics, Inc. plans to submit an Investigational New Drug Application (IND) for its first product candidate in the first quarter of 2019, and to submit INDs for other RCT product candidates in 2019, 2020 and later.
Since its establishment in 2013, Rubius Therapeutics, Inc. has raised a total of 240 million US dollars.
Rubius Therapeutics (RUBY) investment:
Rubius Therapeutics, Inc. (NASDAQ:RUBY) submitted its IPO prospectus on 6/22/2018 and listed on NASDAQ on 7/18/2018. The planned issue price is US$20-22, the actual issue price is US$23, and the issue is 950. 10,000 shares, raising US$218.5 million. Joint underwriting by JP Morgan / Morgan Stanley / Jefferies / Leerink Partners.